US FDA Races To List Essential Medicines For Domestic Manufacture By White House Deadline
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
You may also be interested in...
The Trump administration’s move to strengthen domestic manufacture of essential medicines raises a lot of questions – and industry’s ire.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.
Not all technology platforms provide the expected benefit of filling in CMC review gaps and speeding coronavirus vaccine approvals.